Glaukos Reports Strong Q4 & Full-Year 2025 Results, Reaffirms 2026 Guidance, Advances Key Therapies
GKOS sits 45% above its 52-week low of $73.16.
Summary
Glaukos Corporation announced robust financial results for Q4 and full-year 2025, with significant sales growth driven by key product launches, reaffirmed its 2026 revenue guidance, and provided positive updates on its pipeline.
Key Events · Earnings and Guidance · GKOS
-
Strong Sales Growth Reported
Glaukos achieved record net sales of $143.1 million in Q4 2025, representing a 36% year-over-year increase, and full-year 2025 net sales of $507.4 million, up 32% from the prior year.
-
2026 Revenue Guidance Reaffirmed
The company reaffirmed its net sales guidance for 2026, expecting revenues to be in the range of $600 million to $620 million.
-
Non-Cash Impairment Charge Recorded
A one-time, non-cash impairment charge of $112.9 million was recognized in Q4 2025, related to an acquired intangible asset associated with the transition from Photrexa to Epioxa.
-
Key Product Pipeline Advancements
Glaukos announced FDA approval for unlimited re-administration of iDose TR and commenced initial commercial launch plans for Epioxa following its October 2025 FDA approval, with drug availability expected in late Q1 2026.
Analysis · GKOS · Industrial Applications And Services
Glaukos Corporation reported strong financial performance for the fourth quarter and full fiscal year 2025, highlighted by substantial net sales growth. Fourth-quarter net sales increased 36% year-over-year to $143.1 million, while full-year net sales rose 32% to $507.4 million, driven by the successful adoption of iDose TR and broader Interventional Glaucoma initiatives. Despite a GAAP net loss of $133.7 million in Q4 2025, which included a one-time, non-cash impairment charge of $112.9 million related to the transition from Photrexa to Epioxa, the company's non-GAAP net loss improved significantly. Glaukos reaffirmed its 2026 net sales guidance of $600 million to $620 million, signaling confidence in continued growth. The company also provided positive updates on its robust pipeline, including FDA approval for unlimited re-administration of iDose TR and the commencement of commercial launch plans for Epioxa, further strengthening its position in ophthalmic pharmaceuticals and medical technology.
At the time of this filing, GKOS was trading at $106.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $73.16 to $161.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.